Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Plos One|October 8, 2013
Exploring leptin antagonism in ophthalmic cell modelsLaura Scolaro, Cristina Parrino, Roberta Coroniti, et al.
Expert Review of Endocrinology & Metabolism|February 21, 2019
Leptin-based therapeuticsLaura Scolaro, Marco Cassone, Jerzy W Kolaczynski, et al.
Frontiers in Molecular Biosciences|October 30, 2016
Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis ModelsRoberta Coroniti, Rafal Fario, Didier J Nuno, et al.
Frontiers in Molecular Biosciences|November 24, 2016
Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis ModelsRoberta Coroniti, Rafal Farjo, Didier J Nuno, et al.
Cancer Research|November 2, 2019
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS SignalingGrace E Coggins, Alvin Farrel, Komal S Rathi, et al.
Brain Pathology (Zurich, Switzerland)|September 25, 2009
Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancyMirko Riolfi, Rita Ferla, Luis Del Valle, et al.
Biochimica Et Biophysica Acta|June 17, 2008
Development of a pharmacologically improved peptide agonist of the leptin receptorLaszlo Otvos, Marianna Terrasi, Sandra Cascio, et al.
Biopolymers|June 22, 2010
Peptide-based leptin receptor antagonists for cancer treatment and appetite regulationLaszlo Otvos, Ilona Kovalszky, Laura Scolaro, et al.
Cancer Research|July 9, 2017
Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP InhibitorsSaswati N Chand, Mahsa Zarei, Matthew J Schiewer, et al.
Cancer Discovery|July 31, 2024
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister CellsLiron D Grossmann, Chia-Hui Chen, Yasin Uzun, et al.
Pageof 2